US-based laboratory equipment supplier StatLab Medical Products has agreed to acquire Diapath, an Italian manufacturer of histology and cytology products and equipment.
Diapath will bring advanced equipment, manufacturing capabilities, and an established customer base across Europe, Asia-Pacific, the Middle East and Africa, and Latin America
The acquisition will allow StatLab to expand its market access, unlock significant potential for growth, and enhance its global footprint.
The proposed transaction is anticipated to be completed during the third quarter of this year, subject to regulatory approvals.
Upon closing, Diapath founder Vladimiro Bergamini will be appointed as a senior adviser, and Diapath chief operating officer Alberto Battistel as managing director at StatLab.
StatLab CEO Sung-Dae Hong said: “This combination is a pivotal milestone in our strategy to manufacture the full array of products supporting the entire anatomic pathology workflow.
“Our partnership with Diapath will provide an opportunity to expand their equipment brand throughout global markets, including the US.
“The combination will also enhance StatLab’s European market access for slides, cassettes, and printers, driving our product innovation and manufacturing excellence to the next level.
“I’m excited to welcome Alberto and the talented Diapath team to StatLab and continue to build upon the legacy Vladimiro and his family have developed over the past three decades.”
Established in 1997 in Martinengo, Italy, Diapath expanded its business beyond consumables manufacturing and into the design, development, and production of core histology instruments.
The company’s equipment portfolio includes tissue processors, stainers, embedding centres, and microtomes, building on its advanced development process and Italian design and quality.
Its T-Filler Automatic Formalin dispenser protects technicians from chemical exposure while ensuring specimens receive the correct ratio of formalin.
In addition to its extensive presence in Italy, Diapath’s subsidiaries support the growth of the company’s laboratory products in Germany and France.
Diapath CEO and president Vladimiro Bergamini said: “The decision to join StatLab is driven by our shared commitment to growth and innovation to meet customer needs.
“Our combined company will be uniquely positioned to further expand Diapath’s brand and business, together transforming the anatomic pathology market through innovative development and manufacturing.
“I’m looking forward to the work my team will do with Dae and StatLab to leverage our combined global manufacturing capabilities to capture new business opportunities.”
